Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the stock’s rating to Underperform, noting that the impact of Biogen’s (NASDAQ:BIIB) ...

Sage already has one drug on the market in Zulresso (brexanolone), an intravenously-administered drug for postpartum depression (PPD), but sales of that are small at around $1.5 million per ...

A new study has found that a compound that’s often used in hair loss products has a promising effect on reversing Alzheimer’s ...

Sage stock collapsed to a record low. Please watch the video at Investors.com - How To Sell Stocks: Long-Term Trend Lines Wedbush analyst Laura Chico says it's hard to tell whether the drug failed ...

Biogen's $3 billion alliance with Sage Therapeutics has suffered another setback after their drug for essential tremor failed to move the needle in a phase 2 study. Topline results from the ...

There was food on the dresser, and the TV was paused on "Euphoria," a drama featuring a troubled teenage drug addict. The ...

This shakeup came as Sage decided to focus resources on its ongoing launch of its approved drug Zurzuvae for postpartum depression, as well as to “focus pipeline development efforts” in ...